News EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 Staff September 11, 2023 Iframe sync Post navigation Previous: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerNext: Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer More Stories Neuroscience News Personal Data Craig Chambliss of Neurelis recognized as Entrepreneur Of The Year® 2026 National Overall Award Winner Staff November 20, 2026 News GLP-1 Questions to Ask Your Doctor: Meant Shares What to Bring to the Conversation Staff November 20, 2026 News Nutrition Asheville Pediatric Dentist Blue Ridge Pediatric Dentistry Launches New Website for Western North Carolina Families Staff November 20, 2026